Cost-effectiveness analyses demonstrate that GLP-1 therapy can be justified when accounting for downstream reductions in diabetes complications, cardiovascular events, and improvements in quality-adjusted life years (QALYs). The gene discussed is GLP1R; the disease is diabetes mellitus.